Edition:
India

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

26.65USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$26.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,522
52-wk High
$28.00
52-wk Low
$15.57

Chart for

About

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $948.89
Shares Outstanding(Mil.): 38.39
Dividend: --
Yield (%): --

Financials

BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis

* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage:

03 Apr 2018

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

23 Mar 2018

'Pharma bro' Shkreli seeks 12 to 18 month sentence, below guidelines

NEW YORK Martin Shkreli, the former drug company executive convicted of defrauding investors in two hedge funds he ran, has asked a federal judge to sentence him to 12 months to 18 months in prison, much less than suggested federal guidelines.

28 Feb 2018

UPDATE 1-'Pharma bro' Shkreli seeks 12 to 18 month sentence, below guidelines

NEW YORK, Feb 28 Martin Shkreli, the former drug company executive convicted of defrauding investors in two hedge funds he ran, has asked a federal judge to sentence him to 12 months to 18 months in prison, much less than suggested federal guidelines.

28 Feb 2018

'Pharma bro' Shkreli seeks 12 to 18 month sentence, below guidelines

NEW YORK, Feb 28 Martin Shkreli, the former drug company executive convicted of defrauding investors in two hedge funds he ran, has asked a federal judge to sentence him to 12 months to 18 months in prison, much less than suggested federal guidelines.

28 Feb 2018

BRIEF-Retrophin Inc Q4 Loss Per Share $0.45

* RETROPHIN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

28 Feb 2018

'Pharma bro' Shkreli to be held responsible for $10.4 million in losses: U.S. judge

NEW YORK Former U.S. drug company executive Martin Shkreli will be held responsible for $10.4 million in financial losses when he is sentenced for defrauding investors, a federal judge ruled on Monday, rejecting his argument that he did not cause any losses because his investors eventually came out ahead.

26 Feb 2018

'Pharma bro' Shkreli to be held responsible for $10.4 mln in losses - U.S. judge

NEW YORK, Feb 26 Former U.S. drug company executive Martin Shkreli will be held responsible for $10.4 million in financial losses when he is sentenced for defrauding investors, a federal judge ruled on Monday, rejecting his argument that he did not cause any losses because his investors eventually came out ahead.

26 Feb 2018

BRIEF-Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018

* ‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​

08 Jan 2018

BRIEF-Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001

* RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU)

05 Jan 2018

Earnings vs. Estimates